Study analysis · European Heart Journal · 2025
If you have type 2 diabetes, your blood could be screaming a 70% death risk—and doctors are missing it.
People with type 2 diabetes who have high levels of certain blood inflammation markers are more than three times as likely to die or have a heart event over 11 years.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at people with diabetes and noticed that those with higher levels of certain blood markers tended to have more heart problems or die sooner. But it didn’t change anything to see if the markers caused the problems — it just watched what happened over time.
What’s the bottom line?
Doctors tested blood markers of inflammation in people with type 2 diabetes to see who might have heart problems or die sooner.
How strong is this study?
This study did a really good job tracking people for over 10 years and adjusting for things like age and blood pressure. But since it didn’t randomly assign treatments or control everything, we can’t be 100% sure the blood markers are the reason for the bad outcomes — maybe something else was involved.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
37 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=925)+19.8/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study without randomization or intervention; it can identify associations but cannot rule out confounding factors or establish that biomarkers directly cause increased mortality or MACE.
No Conflicts
No conflicts of interest identified
No conflicts identified
Funders
Conflict Details
Copenhagen University Hospital-Steno Diabetes Center Copenhagen: Employed by the funding institution
Copenhagen University Hospital-Herlev: Employed by a participating hospital institution
Copenhagen University Hospital-Hvidovre: Employed by a participating hospital institution
Copenhagen University Hospital-Herlev: Employed by a participating hospital institution
Copenhagen University Hospital-Steno Diabetes Center Copenhagen: Employed by the funding institution
+1 more conflicts
All authors are affiliated with public hospital institutions; no industry funding or commercial ties are disclosed. The study appears to be independently conducted with no evidence of funder influence beyond financial support.
Key takeaways
- 01
People with the highest suPAR levels had a 70% chance of dying over 11 years; those with the lowest had only 19%.
- 02
Having two high inflammation markers doubled or tripled the risk of death or heart events.
- 03
Yes — this means inflammation levels can help identify diabetic patients at highest risk, even when other risk factors are accounted for.
Surprising findings
- suPAR was the strongest predictor of death—far outperforming IL-6 and hsCRP—with a 70% mortality rate in the top tertile.Most public health messaging focuses on hsCRP as the go-to inflammation marker—this study shows suPAR, a lesser-known protein, is the real red flag for diabetics.
- The study achieved 100% follow-up over 11.4 years—unheard of in observational research.Most long-term studies lose 20-40% of participants to dropout or lost contact—this one tracked every single person, making the data unusually reliable.
Practical takeaways
Ask your doctor for suPAR, IL-6, or hsCRP tests if you have type 2 diabetes—especially if you’re at moderate risk by standard measures.
These tests aren’t widely available or covered by insurance yet, and lowering them isn’t yet proven to extend life.
high confidenceWhy this study matters
70% vs 19%: The suPAR Shock
In this 11.4-year study of 925 people with type 2 diabetes, those in the top third of suPAR levels had a 70% mortality rate—nearly four times higher than the 19% rate in the bottom third. This single biomarker outperformed traditional risk factors in predicting death.
Most people think blood sugar controls their diabetes risk—but this shows inflammation might be the silent killer no one’s testing for.
Two Markers = Double the Danger
Having two elevated inflammatory biomarkers (suPAR + IL-6, suPAR + hsCRP, or IL-6 + hsCRP) increased the risk of death or heart events by 1.9 to 2.5 times—even after adjusting for age, blood pressure, and cholesterol. The highest risk combo? suPAR + hsCRP (HR 2.5).
It’s not just one bad marker—it’s the combo that turns a moderate risk into a crisis. This changes how we think about risk stacking.
The Risk Model That Got Smarter
Adding just three blood tests—suPAR, IL-6, and hsCRP—to the standard SCORE2-Diabetes model improved its ability to correctly reclassify patients into higher or lower risk categories. This means doctors could stop guessing who’s in danger.
It’s rare for a simple blood test to make a major risk model significantly better—this could change how diabetes care is personalized.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Doctors tested blood markers of inflammation in people with type 2 diabetes to see who might have heart problems or die sooner.
Research results
People with the highest suPAR levels had a 70% chance of dying over 11 years; those with the lowest had only 19%. Having two high inflammation markers doubled or tripled the risk of death or heart events.
What this means - more context
Yes — this means inflammation levels can help identify diabetic patients at highest risk, even when other risk factors are accounted for.
This study investigates whether inflammatory biomarkers (suPAR, IL-6, hsCRP) predict mortality and major adverse cardiovascular events (MACE) in adults with type 2 diabetes, independent of established risk factors.
In a 11.4-year prospective cohort of 925 adults with type 2 diabetes, elevated baseline levels of suPAR, IL-6, and hsCRP were independently associated with higher all-cause mortality and MACE. Individuals in the top tertile of suPAR had a 70% mortality rate versus 19% in the bottom tertile. Combining two elevated biomarkers increased risk 1.9- to 2.5-fold. Adding these biomarkers improved risk reclassification beyond the SCORE2-Diabetes model.
Methods Used
Prospective cohort study measuring baseline suPAR, IL-6, and hsCRP in 925 adults with type 2 diabetes; outcomes were all-cause mortality and MACE (composite of cardiovascular hospitalizations or death); associations were analyzed using Cox models adjusted for SCORE2-Diabetes variables and albuminuria; net reclassification improvement (NRI) and C-statistics assessed model improvement.
Main Finding
Elevated suPAR, IL-6, and hsCRP independently predict mortality and MACE in type 2 diabetes; combining two biomarkers increased hazard ratios to 1.9–2.5 (all P<0.001), and adding them to SCORE2-Diabetes improved risk reclassification.
Confidence Level
High confidence due to long-term prospective design, 100% follow-up, adjustment for major confounders, and reporting of effect sizes with confidence intervals and p-values.
Study Flags
Red Flags
- •No randomization
- •No blinding reported
- •Potential for residual confounding despite adjustments
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
suPAR was the strongest predictor of death—far outperforming IL-6 and hsCRP—with a 70% mortality rate in the top tertile.
Most public health messaging focuses on hsCRP as the go-to inflammation marker—this study shows suPAR, a lesser-known protein, is the real red flag for diabetics.
Practical Takeaways
Ask your doctor for suPAR, IL-6, or hsCRP tests if you have type 2 diabetes—especially if you’re at moderate risk by standard measures.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at people with diabetes and noticed that those with higher levels of certain blood markers tended to have more heart problems or die sooner. But it didn’t change anything to see if the markers caused the problems — it just watched what happened over time.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Prospective design with long-term follow-up (median 11.4 years)
- 100% follow-up rate, minimizing attrition bias
- Adjustment for 10+ established risk factors (SCORE2-Diabetes model, albuminuria)
Weaknesses
- No randomization or intervention — cannot establish causation
- Blinding status unknown — potential for measurement or assessment bias
- Single-center study from Denmark — limited geographic and ethnic diversity
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Doctors tested blood markers of inflammation in people with type 2 diabetes to see who might have heart problems or die sooner.
Research results
People with the highest suPAR levels had a 70% chance of dying over 11 years; those with the lowest had only 19%. Having two high inflammation markers doubled or tripled the risk of death or heart events.
What this means - more context
Yes — this means inflammation levels can help identify diabetic patients at highest risk, even when other risk factors are accounted for.
This study investigates whether inflammatory biomarkers (suPAR, IL-6, hsCRP) predict mortality and major adverse cardiovascular events (MACE) in adults with type 2 diabetes, independent of established risk factors.
In a 11.4-year prospective cohort of 925 adults with type 2 diabetes, elevated baseline levels of suPAR, IL-6, and hsCRP were independently associated with higher all-cause mortality and MACE. Individuals in the top tertile of suPAR had a 70% mortality rate versus 19% in the bottom tertile. Combining two elevated biomarkers increased risk 1.9- to 2.5-fold. Adding these biomarkers improved risk reclassification beyond the SCORE2-Diabetes model.
Methods Used
Prospective cohort study measuring baseline suPAR, IL-6, and hsCRP in 925 adults with type 2 diabetes; outcomes were all-cause mortality and MACE (composite of cardiovascular hospitalizations or death); associations were analyzed using Cox models adjusted for SCORE2-Diabetes variables and albuminuria; net reclassification improvement (NRI) and C-statistics assessed model improvement.
Main Finding
Elevated suPAR, IL-6, and hsCRP independently predict mortality and MACE in type 2 diabetes; combining two biomarkers increased hazard ratios to 1.9–2.5 (all P<0.001), and adding them to SCORE2-Diabetes improved risk reclassification.
Confidence Level
High confidence due to long-term prospective design, 100% follow-up, adjustment for major confounders, and reporting of effect sizes with confidence intervals and p-values.
Study Flags
Red Flags
- •No randomization
- •No blinding reported
- •Potential for residual confounding despite adjustments
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
suPAR was the strongest predictor of death—far outperforming IL-6 and hsCRP—with a 70% mortality rate in the top tertile.
Most public health messaging focuses on hsCRP as the go-to inflammation marker—this study shows suPAR, a lesser-known protein, is the real red flag for diabetics.
Practical Takeaways
Ask your doctor for suPAR, IL-6, or hsCRP tests if you have type 2 diabetes—especially if you’re at moderate risk by standard measures.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at people with diabetes and noticed that those with higher levels of certain blood markers tended to have more heart problems or die sooner. But it didn’t change anything to see if the markers caused the problems — it just watched what happened over time.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Prospective design with long-term follow-up (median 11.4 years)
- 100% follow-up rate, minimizing attrition bias
- Adjustment for 10+ established risk factors (SCORE2-Diabetes model, albuminuria)
Weaknesses
- No randomization or intervention — cannot establish causation
- Blinding status unknown — potential for measurement or assessment bias
- Single-center study from Denmark — limited geographic and ethnic diversity
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study did a really good job tracking people for over 10 years and adjusting for things like age and blood pressure. But since it didn’t randomly assign treatments or control everything, we can’t be 100% sure the blood markers are the reason for the bad outcomes — maybe something else was involved.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
37 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=925)+19.8/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 552 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study without randomization or intervention; it can identify associations but cannot rule out confounding factors or establish that biomarkers directly cause increased mortality or MACE.
No Conflicts
No conflicts of interest identified
No conflicts identified
Funders
Conflict Details
Copenhagen University Hospital-Steno Diabetes Center Copenhagen: Employed by the funding institution
Copenhagen University Hospital-Herlev: Employed by a participating hospital institution
Copenhagen University Hospital-Hvidovre: Employed by a participating hospital institution
Copenhagen University Hospital-Herlev: Employed by a participating hospital institution
Copenhagen University Hospital-Steno Diabetes Center Copenhagen: Employed by the funding institution
+1 more conflicts
All authors are affiliated with public hospital institutions; no industry funding or commercial ties are disclosed. The study appears to be independently conducted with no evidence of funder influence beyond financial support.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
6 researchersIf this is your work, this is how we attribute it on Fit Body Science. Hashmat Sayed Zohori Bahrami is listed as the lead author.